和誉-B(02256.HK):口服小分子pan-KRAS抑制剂ABSK211新药临床试验申请获NMPA批准

智通财经
Aug 19
【和誉-B(02256.HK):口服小分子pan-KRAS抑制剂ABSK211新药临床试验申请获NMPA批准】智通财经APP讯,和誉-B(02256.HK)发布公告,中国国家药品监督管理局(NMPA)已批准ABSK211的新药临床试验(IND)申请。ABSK211是一款口服、高效力小分子pan-KRAS抑制剂,对多种KRAS基因改变具有广谱活性,用于治疗携带KRAS基因改变的晚期实体瘤患者。此前, ABSK211已于7月8日获得美国食品药品监督管理局(FDA)的IND批准。在中国及美国均获得IND批准是ABSK211全球临床开发计划的关键里程碑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10